1st Quarter - Report

APCO WORLDWIDE LLC for HIKMA PHARMACEUTICALS USA INC.

Period 1st Quarter 2026 Filed Apr 20, 2026 Signed by Jonathan Friedman

Official filing
Firm
APCO WORLDWIDE LLC
Client
HIKMA PHARMACEUTICALS USA INC.
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health and pharmaceutical policies and domestic pharmaceutical manufacturing supply chain issues and drug shortage issues

Foreign entity interest: Hikma Pharmaceuticals PLC, identified in the LD-1, has an indirect interest in U.S. policy relating to health and pharmaceutical products.

LobbyistCovered position, as disclosed
MIKASA MODI —
ALLISON PARKER-LAGOO Assistant to the Chief of Staff, Sen. Hagan
DAN SCANDLING Chief of Staff & Press Secretary, Rep. Bateman

Contacted: State, Dept of (DOS); SENATE; Commerce, Dept of (DOC); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Trade policies impacting domestic generic pharmaceutical manufacturing

Foreign entity interest: Hikma Pharmaceuticals PLC, identified in the LD-1, has an indirect interest in U.S. policy relating to health and pharmaceutical products.

LobbyistCovered position, as disclosed
MIKASA MODI —
ALLISON PARKER-LAGOO Assistant to the Chief of Staff, Sen. Hagan
DAN SCANDLING Chief of Staff & Press Secretary, Rep. Bateman

Contacted: SENATE; State, Dept of (DOS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.